These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21132272)
1. Development of a drug resistance model for hepatoblastoma. Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S Int J Oncol; 2011 Feb; 38(2):447-54. PubMed ID: 21132272 [TBL] [Abstract][Full Text] [Related]
2. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Warmann SW; Heitmann H; Teichmann B; Gratz KF; Ruck P; Hunger M; Fuchs J Pediatr Hematol Oncol; 2005; 22(5):373-86. PubMed ID: 16020127 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965 [TBL] [Abstract][Full Text] [Related]
4. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737. Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825 [TBL] [Abstract][Full Text] [Related]
5. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637 [TBL] [Abstract][Full Text] [Related]
6. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Warmann S; Hunger M; Teichmann B; Flemming P; Gratz KF; Fuchs J Cancer; 2002 Oct; 95(8):1795-801. PubMed ID: 12365029 [TBL] [Abstract][Full Text] [Related]
7. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin. Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521 [TBL] [Abstract][Full Text] [Related]
8. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605 [TBL] [Abstract][Full Text] [Related]
9. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893 [TBL] [Abstract][Full Text] [Related]
11. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543 [TBL] [Abstract][Full Text] [Related]
12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
13. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613 [TBL] [Abstract][Full Text] [Related]
14. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of cIAP1 in the effective suppression of chemotherapy‑resistant hepatoblastoma. Tsukada R; Nomura M; Ueno T; Okuyama H Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211761 [TBL] [Abstract][Full Text] [Related]
17. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188 [TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. Soini T; Pihlajoki M; Kyrönlahti A; Andersson LC; Wilson DB; Heikinheimo M Tumour Biol; 2017 Mar; 39(3):1010428317695016. PubMed ID: 28349834 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Minemura M; Tanimura H; Tabor E Int J Oncol; 1999 Sep; 15(3):559-63. PubMed ID: 10427140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]